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and Jon Clardy1*
Background: Dihydroorotate dehydrogenase (DHODH) catalyzes the fourth
committed step in the de novo biosynthesis of pyrimidines. As rapidly
proliferating human T cells have an exceptional requirement for de novo
pyrimidine biosynthesis, small molecule DHODH inhibitors constitute an
attractive therapeutic approach to autoimmune diseases, immunosuppression,
and cancer. Neither the structure of human DHODH nor any member of its
family was known.
Results: The high-resolution crystal structures of human DHODH in complex
with two different inhibitors have been solved. The initial set of phases was
obtained using multiwavelength anomalous diffraction phasing with
selenomethionine-containing DHODH. The structures have been refined to
crystallographic R factors of 16.8% and 16.2% at resolutions of 1.6 Å and
1.8 Å for inhibitors related to brequinar and leflunomide, respectively.
Conclusions: Human DHODH has two domains: an α/β-barrel domain containing
the active site and an α-helical domain that forms the opening of a tunnel leading
to the active site. Both inhibitors share a common binding site in this tunnel, and
differences in the binding region govern drug sensitivity or resistance. The active
site of human DHODH is generally similar to that of the previously reported
bacterial active site. The greatest differences are that the catalytic base removing
the proton from dihydroorotate is a serine rather than a cysteine, and that packing
of the flavin mononucleotide in its binding site is tighter.
Introduction
Although most cells meet their requirements for
nucleotides by recycling existing ones, activated T cells
and other rapidly proliferating cells depend heavily on de
novo nucleotide synthesis [1–3]. In addition to DNA and
RNA synthesis, rapidly proliferating human T cells
require de novo pyrimidine biosynthesis for protein glyco-
sylation, membrane-lipid biosynthesis, and strand-break
repair [1–3]. The therapeutic potential of inhibiting de
novo pyrimidine biosynthesis at the dihydroorotate dehy-
drogenase (DHODH) catalyzed step was revealed by the
antiproliferative agents leflunomide and brequinar [4,5]
(Figure 1). Both compounds and many analogs are potent
and selective inhibitors of mammalian DHODH [4,5]. The
inhibitory mechanisms of leflunomide, which was recently
approved for the treatment of rheumatoid arthritis, and bre-
quinar, which was in clinical trials for cancer and host-
versus-graft disease, are not known [6–10]. To define the
structural basis of the potency and specificity of inhibitors
related to both leflunomide and brequinar we have deter-
mined the high-resolution (1.6–1.8 Å) crystal structures of
human DHODH in complex with A771726, the active form
of leflunomide, and a brequinar analog. These structures
reveal the common binding region shared by each inhibitor. 
DHODHs, which catalyze the only redox step in pyrimi-
dine biosynthesis, are divided into two large families, and
the mammalian enzymes form a tightly clustered group in
family 2 [11] (Figure 2). Oxidation of dihydroorotate
(DHO) to orotate (ORO) and reduction of flavin mono-
nucleotide (FMN) to dihydroflavin mononucleotide
(FMNH2) comprise the two half reactions of the redox
couple (Figure 1a). In family 1 DHODHs, oxygen or some
water-soluble molecules such as fumarate or NAD+
oxidize FMNH2 to regenerate FMN, and the enzymes are
cytosolic [12]. For human DHODH, ubiquinone is the
oxidant (Figure 1a), and the enzyme associates with the
mitochondrial inner membrane [1]. Full-length human
DHODH has 396 residues [13] and the construct used in
this work, which lacks the mitochondrial signal peptide,
comprises Met30 to the C terminus (Figure 2). This con-
struct has full enzymatic activity, remains membrane asso-
ciated, and retains brequinar sensitivity [14]. 
High-resolution crystal structures of human DHODH in
complex with a brequinar analog and the active metabolite
of leflunomide (A771726) have been solved. Although the
overall α/β-barrel structure resembles a bacterial family 1
DHODH structure, there are significant differences in the
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active site and the N-terminal extension [15,16]. In
human DHODH serine replaces the cysteine catalytic
base of the bacterial DHODH. The basicity of the serine
seems to be enhanced by a hydrogen bond to a water that
is bound to the face of an aromatic ring. The long N-ter-
minal extension, which characterizes the membrane-
bound DHODHs, folds into a helical domain that forms
the entrance of a tunnel leading into the active site. The
helical domain seems to be responsible for the membrane
association of human DHODH. Both the brequinar analog
and A771726, the leflunomide active metabolite, bind in
the same region of this tunnel: a constriction near the
flavin mononucleotide.
Results and discussion
The overall structure
The enzyme contains two domains connected by
an extended loop: a small N-terminal domain
(Met30–Leu68) and a large C-terminal domain (Met78 to
the C terminus) (Figure 3). The large domain has an α/β-
barrel fold with a central barrel of eight parallel β strands
(β1–β8) surrounded by eight α helices (α3, α4, α6–α10
and α12) (Figure 3). At the top of the barrel three short
antiparallel β strands βC, βD and βE) form a rigid side for
the proximal redox site (Figure 3). A pair of antiparallel
β strands, βA and βB, are at the bottom of the barrel
(Figure 3). The small N-terminal domain consists of two
α helices, α1 and α2, and a short loop connecting them. It
packs against the α/β barrel at the side close to βC and βD
(Figure 3). The extended loop, which has few interactions
with the rest of the protein, connects the C terminus of α2
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Figure 1
Reactions and inhibitors of human
dihydroorotate dehydrogenase. (a) The
reactions occurring in the proximal and distal
redox sites of human dihydroorotate
dehydrogenase (DHODH). The hydrogen
denoted as H* is transferred to FMN as a
hydride, and the hydrogen denoted H′ is lost as
a proton. (b) Chemical structure of the
inhibitors brequinar, leflunomide, and A771726,
which is the active metabolite of leflunomide.
Figure 2
Multiple sequence alignment of selected DHODH sequences.
Residues are colored based on the degree of sequence conservation:
red, identical in all DHODH sequences; blue, identical residue in family
2; cyan, similar residues in all DHODH sequences; and green, identical
residues in family 1. Secondary structures are also labeled. The red
triangle indicates the catalytic base. Residue numbering is based on
human DHODH. The alignment was made with CLUSTALW [32] and
manually corrected. The figure was prepared using the program
ALSCRIPT [33]. The sequences used in the alignment are HUMAN
(human), RAT (rat), DROME (Drosophila melanogaster), RATH
(Arabidopsis thaliana), (SCHPO) (Schizosaccharomyces pombe),
AGRAE (Agrocybe aegerita), ECOLI (Escherichia coli), SALTY
(Salmonella typhimurium), HAEIN (Haemophilus influenzae), SYNY3
(Synechocystis sp.), MYCLE (Mycobacterium leprae), LACLA
(DHODH A from Lactococcus lactis), YEAST (yeast), LACLB
(DHODH B from Lactococcus lactis), ENTFA (Enterococcus faecalis),
BACCL (Bacillus caldolyticus), BACSU (Bacillus subtilis), LACPL
(Lactobacillus plantarum), AQUAE (Aquifex aeolicus), METJA
(Methanococcus jannaschii), METTH (Methanobacterium
thermoautotrophicum), ARCFU (Archaeoglobus fulgidus), and SULSO
(Sulfolobus solfataricus).
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to the bottom of the α/β barrel (Figure 3). The large
domain has three cis-peptide bonds, and two of them, the
cis bonds starting at Gly119 and Val282, seem to be neces-
sary for FMN binding.
The overall fold of the large domain is very similar to
that of Lactococcus lactis DHODH [15], a family 1 protein
with 16% sequence identity to human DHODH
(Figure 2). The Lactococcus enzyme exists as a dimer both
in solution and in the crystal, whereas the human
enzyme is a monomer in solution (based on analytical gel
filtration chromatography data, not shown) and in the
crystal. The root mean square deviation (rmsd) for 256
Cα positions between the two structures is 1.8 Å, and the
two cis peptide bonds essential for FMN binding are
found in both structures. The largest rms differences
between the two structures are informative. The region
Phe98–Val105 (β1–α3 loop) interacts strongly with the
small domain in human DHODH. Asp242–Thr261 (β5
and loops) and Val287–Glu300 are involved in the dimer-
ization of Lactococcus DHODH [15]. 
The membrane-association motif
An N-terminal extension distinguishes family 1 and family
2 DHODHs. Multiple sequence alignments on the avail-
able DHODH sequences show that all known membrane
associated DHODH sequences have an N-terminal exten-
sion that is missing in all cytosolic ones (Figure 2). In
human DHODH, this extension contains the small
domain and the loop connecting it to the large domain. In
the amphipathic small domain, all of the charged and most
of the polar residues orient towards the large domain
whereas the hydrophobic sidechains project away from the
large domain (Figure 4a). The hydrophobic sidechains of
the small domain (Met30, Phe37, Leu49, Leu50, Leu58,
Phe62, Leu65 and Leu67) form a large protruding
hydrophobic patch (Figure 4a). The positively charged
sidechains of residues from the small (Arg36, Arg57,
Arg61, His41 and His56) and large (Arg131, Arg372)
domains form a positively charged fringe at the base of the
hydrophobic protrusion (Figure 4a). There are several salt
bridges and hydrogen bonds between the large and small
domains, and many of the residues involved (Glu53,
His56, Arg133 and Arg136) are completely conserved in
family 2 DHODHs (Figure 2). 
The small domain’s structure suggests its involvement
with membrane association. The protruding hydrophobic
patch could push into the hydrophobic interior of the
membrane while the positively charged periphery would
interact with the negatively charged phospholipid head
groups. In the crystal structure, a detergent molecule
(DDAO) is tightly bound to the center of the hydrophobic
patch with its head group oriented towards the edge
(Figure 4b). A somewhat similar membrane-binding motif
has been observed in the prostaglandin H2 synthase-1
structure, in which three α helices were suggested to
interact with the lipid layer [17]. 
The version of human DHODH used in this work lacks
29 N-terminal amino acids. Knecht et al. have suggested
that these missing N-terminal residues contain a mito-
chondrial signal peptide and a possible transmembrane
peptide of 18 amino acids [18]. Such a transmembrane
peptide could augment the membrane association of
human DHODH, and nothing in our analysis excludes
such a possibility. However, the transmembrane peptide
is not required for membrane association, as shown by
Copeland et al. [14]. Escherichia coli DHODH, which has
an N terminus similar to the protein used in our work
(Figure 2), is also membrane associated.
The inhibitor-binding region
The space between α1 and α2 forms a 10 × 20 Å slot in
the hydrophobic patch, with the short α1–α2 loop at the
narrow end (Figure 4a). This slot forms the entrance to a
tunnel that ends at the FMN cavity beneath the α1–α2
loop. This tunnel narrows as it goes into the proximal
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Figure 3
Stereoview ribbon diagram of human
DHODH. Helices, strands and coils are
colored red, cyan, and green, respectively.
Residues with weak electron density are in
purple. Ligands (the inhibitor shown here is a
brequinar analog) are shown in ball-and-stick
representation with yellow carbon, red oxygen,
blue nitrogen, pink phosphorus, and green
fluorine atoms. Secondary structural elements
and the N and C termini are labeled. This
figure was prepared using MOLSCRIPT [34].
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redox site, and several charged or polar sidechains (Gln47,
His56, Tyr356, Thr360 and Arg136) are located at the
narrow end of the channel (Figure 4b). Ubiquinone, which
can readily diffuse in the mitochondrial inner membrane,
undoubtedly uses this tunnel to approach FMNH2 for a
redox reaction.
A brequinar analog is located in this channel, with the
6-fluoro-3-methyl-4-quinoline carboxylic acid end of the
molecule most deeply buried in the polar environment
and the hydrophobic aromatic rings in the hydrophobic
part of the channel (Figure 4b). The carboxylate hydrogen
bonds to the sidechain of Gln47 and forms a salt bridge
with Arg136 (Figure 4b). The only water observed in the
channel forms hydrogen bonds with Thr360 Oγ and the
carboxylate (Figure 4b). The fluoroquinoline ring stacks
with the imidazole ring of His56, and the His56Ala mutant
of human DHODH is more than 100-fold less sensitive to
brequinar [19]. The 6-fluoro group makes the closest
approach to FMN: 3.8 Å to the C7 methyl. The biphenyl
group has hydrophobic contacts with the sidechains of
Met43, Ala59, Leu68 and Pro364 as well as the detergent
molecule in the mouth of the channel (Figure 3c). These
extensive interactions might explain brequinar’s high
affinity for human DHODH [5].
Metabolic studies have indicated that leflunomide is
rapidly processed in vivo to a primary metabolite
A771726, which mediates the immunosuppressive and
disease-modifying effects of the parent drug (Figure 1)
[20]. A771726 binds to the same site as brequinar
(Figure 5a). The carbonyl is hydrogen bonded to a water,
which in turn is bound to Arg136, while the enolic OH is
hydrogen bonded to Tyr356 (Figure 5a). The trifluoro-
methyl-containing aromatic ring makes numerous
hydrophobic contacts with residues in the tunnel
(Figure 5a). There are fewer inhibitor–protein interac-
tions in the A771726 complex than in the brequinar
complex because of the smaller size of A771726, and the
binding region in the A771726 complex is less ordered
than in the brequinar complex. 
Both A771726 and brequinar use similar features to bind
in the same location, and analysis of these bound
inhibitors illustrates how ubiquinone, the natural sub-
strate, would bind in the same channel. The ubiquinone
head group overlays well with the brequinar quinoline
group and if ubiquinone occupied the same position the
two quinone carbonyl oxygens could accept hydrogen
bonds from Arg136 and Tyr356. Both Arg136 and Tyr356
are completely conserved in family 2 DHODHs, except
for one sequence where the tyrosine residue is one residue
further along (Figure 2). Tyr356 and/or the tightly bound
water that is observed in the brequinar complex could
provide any protons needed to generate a neutral hydro-
quinone after electron transfer from the FMN. 
The structures of the bound inhibitors also highlight key
specificity determinants for different members of family 2
DHODHs. For example, mammalian DHODHs are sen-
sitive to brequinar whereas other family 2 DHODHs,
most notably the E. coli enzyme, are insensitive [5,14].
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Figure 4
The membrane-binding motif and the inhibitor-binding channel of
human DHODH. (a) Surface representation of human DHODH. Acidic,
basic, polar and hydrophobic residues and surfaces are colored red,
blue, magenta and yellow, respectively. Charged residues are labeled.
Brequinar and FMN are represented by black and cyan sticks,
respectively. This figure was prepared using GRASP [35]. (b) The
tunnel leading into the proximal redox site of DHODH. The surface of
the cavity is colored as in (a). Orotate (ORO) and FMN are bound in
the narrow polar region, brequinar is bound in the middle region, and a
detergent (DDAO) is bound at the entrance. This figure was prepared
using MOLSCRIPT [34].
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Val134 in human DHODH is only 3.2 Å from the fluorine
of brequinar and 3.9 Å from the methyl of A771726, and
the corresponding residue in E. coli DHODH is leucine.
Model building shows a steric clash with leucine that
would prevent ligand binding. 
A crucial specificity determinant between family 1 and 2
DHODHs is the hydrophobic channel in which the
inhibitors are bound in human DHODH. Family 1
DHODHs simply have no equivalent tunnel, and the
edge of FMN is exposed to solvent. But there are other
prominent features that discriminate between families 1
and 2, most notably Arg136 and Tyr356 (Figures 2 and 4a).
In family 1 DHODHs the Arg136 equivalent is usually
aspartate or glutamate (in 9 out of 12 sequences), and the
equivalent of Tyr356 is always glycine. The two families
could scarcely have more different charge and shape
determinants in the critical region near FMN.
The orotate-FMN-binding region
In addition to the tunnel for ubiquinone, the distal elec-
tron acceptor, human DHODH has significant changes
in the proximal redox site where dihydroorotate and
FMN bind (Figure 1). Kinetic studies on the dihy-
droorotate–orotate exchange reaction using 14C-labeled
orotate showed that for E. coli DHODH the oxidization of
dihydroorotate by FMN is essentially irreversible. On the
other hand, the exchange reaction is considerably faster
for Lactococcus DHODH [21]. Fluorescence studies on
bound FMN suggest much tighter binding in E. coli
DHODH than in Lactococcus DHODH [21]. In our struc-
tures the aromatic ring of orotate is almost parallel to
FMN and is 3.2–3.8 Å from its si face (Figure 5b). Oro-
tate’s other face is completely covered by the
Asn212–Gly226 loop. The location and orientation of
orotate in human DHODH is essentially the same as in
the Lactococcus DHODH–orotate complex structure [16].
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Figure 5
Binding of A771726 in the hydrophobic
channel of human DHODH. (a) Stereoview
of the binding interactions of A771726.
Ligands are shown in ball-and-stick
representation, and residues interacting with
A771726 are represented by thin sticks.
Hydrogen bonds are shown as dashed black
lines. (b) A 2Fo–Fc electron-density map of
A771726, FMN and orotate contoured at
1.2σ (1.8 Å). Ligands and selected DHODH
residues in the vicinity are shown in ball-and-
stick representation. This figure was
prepared with MOLSCRIPT [34].
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The weaker electron density and higher temperature
factors of this loop suggest that it opens to admit dihy-
droorotate and release orotate from a closed active site.
There are several highly conserved residues at the ends of
this flexible loop. Asn212, Ser214 and Pro216 are con-
served in all DHODHs, and in family 2 Leu221, Arg222
and Gln225 are conserved and a leucine/methionine at 224
is conservatively substituted (Figure 2).
Kinetic studies on bovine liver mitochondria DHODH
have shown that a general base abstracts a proton from the
C5 position of dihydroorotate [22] (Figure 1). The sub-
strate is held in place by two completely conserved
asparagine residues (145 and 284), and the closest protein
atom to C5 in human DHODH is Ser215 Oγ (3.2 Å)
(Figure 5b). Ser215, which is completely conserved in
family 2 DHODHs, is essential for catalysis in E. coli
DHODH, a family 2 member [21]. It’s likely that Ser215
plays the role of catalytic base in human DHODH, and
such a role would be unusual for a serine. The Oγ of
Ser215 hydrogen bonds to a tightly bound water molecule,
which in turn hydrogen bonds to Thr218 Oγ1 and the pi
electron cloud of Phe149 (Figure 5b). Both Thr218 and
Phe149 are conserved in family 2 DHODHs, and this
series of hydrogen bonds and pi interactions could both
enhance the basicity of the Ser215 sidechain and stabilize
its position during the reaction. In family 1, the catalytic
base is cysteine and Thr218 and Phe149 are valine and
leucine, respectively [11,16]. 
In the reduction of FMN to FMNH2, N5 and possibly N1
of the flavin form new N–H bonds (Figure 1). N5 receives
the hydride from C6 of dihydroorotate, and the N5–C6
distance of 3.6 Å is compatible with direct hydride transfer
(Figures 1 and 5b). N1 could be negatively charged or pro-
tonated, and Lys255, which is conserved in all known
DHODH sequences but one, could serve either as a
proton donor or as a negative charge stabilizer. 
FMN and orotate have extensive hydrophobic contacts
and form multiple hydrogen bonds with human DHODH.
These interactions are generally similar to those observed
in the Lactococcus DHODH structure [15,16], and several
of the interacting residues (Asn145, Gly148, Asn212,
Asn284, Gly306 and Gly335) are conserved in all
DHODH sequences (Figures 2 and 5b). Others are mostly
conserved (Gly97 and Lys225) or conservatively substi-
tuted (Thr285Ser and Asn217His). Lys100, which is con-
served in family 2 members, forms hydrogen bonds with
FMN and the carboxylate of orotate, and Lys43 plays an
equivalent role in family 1 DHODHs. Ser120 and Thr357
have a common role in Lactococcus and human DHODH. 
One major difference between the human and Lactococcus
DHODH structures is the dimethylbenzene ring of FMN,
which is tightly packed against sidechains in the human
but not in the bacterial enzyme. In the human enzyme,
Asn145, Tyr356 and Tyr147 all cluster about the sides of
the dimethylbenzene ring of FMN, and this packing
would explain the tighter binding and more negative
redox potential of family 2 than family 1 DHODHs [21].
The dimethyl end of the ring is exposed to the hydro-
phobic channel, and this is presumably the region in
which the second redox reaction between FMNH2 and
ubiquinone takes place.
In each complex model there is a sulfate ion and an
acetate ion. Both ions are located at the protein surface
and are far away from either the inhibitor-binding region
or the orotate-FMN-binding region.
Biological implications
The structures reported here illuminate two facets of
human dihydroorotate dehydrogenase (DHODH): the
three-dimensional organization of its catalytic site and
the binding motifs of potential therapeutic agents. The
first is important for understanding the mechanistic
enzymology of pyrimidine biosynthesis; the second will
suggest designs for better therapies for diseases charac-
terized by rapidly proliferating cells. 
DHODH has two redox sites, one where FMN oxidizes
dihydroorotate to orotate and another where ubiquinone
oxidizes FMNH2 to FMN. The bound orotate and
FMN clearly define one redox site of human DHODH,
and it resembles in organization but not in detail the
redox site of a bacterial DHODH. The most surprising
difference between the human and bacterial enzymes is
a serine replacing a cysteine as the catalytic base. This
catalytic serine, Ser215, is conserved in family 2
DHODHs. Two other completely conserved residues,
Thr218 and Phe149, along with a tightly bound water
molecule could function to enhance the basicity of
Ser215. A more complete understanding of the catalytic
mechanism will require further work.
The structures also reveal that the long N-terminal
extension that characterizes family 2 DHODHs forms a
helical membrane-associated motif, which forms the
mouth of a hydrophobic tunnel leading into the
FMNH2–ubiquinone redox site. The inhibitors bind to a
narrow region in this tunnel, and this location has inter-
esting implications for structure-based drug design. Leo
Tolstoy’s well-known description of families — “All
happy families resemble one another, each unhappy
family is unhappy in its own way” — finds an analogy in
enzymes. All DHODH active sites resemble one
another. They must because they all carry out the same
reaction. Regions near active sites can differ. In human
DHODH the residues that interact with the inhibitors
differ markedly from one organism to another, and a
single residue change can confer resistance. Future ther-
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apeutic agents, both those targeted to rapidly proliferat-
ing human cells and those targeted to human pathogens,
could be designed to explicitly exploit these differences.
Materials and methods
Protein expression and purification
The cDNA encoding an N-terminally truncated human DHODH
(Met30–Arg396) was amplified by the polymerase chain reaction
(PCR) and cloned into pET-19b plasmid (Novagen, Madison, WI). The
vector produces human DHODH as an N-terminal ten-histidine fusion
protein. The plasmid pET-19b–human DHODH was transformed into
BL21 (DE3) pyrD E. coli cells for protein production. Cells were grown
at 25°C in a rich medium [23], and were induced with 1 µM isopropyl-
β-D-thiogalactoside at an OD600 of 0.6–0.8. Cells were harvested after
an additional 20 h of growth. A cell pellet from 1 l of culture was lysed
in 100 ml of buffer A (50 mM HEPES pH 7.7, 300 mM NaCl, 10%
glycerol). Triton X-100 was added to a final concentration of 1% into
the lysate before centrifugation at 48,000 × g for 30 min. The super-
natant was incubated with 3 ml TALON beads (Clontech) for an hour.
Triton X-100 was exchanged by washing with 10 mM N,N-dimethylun-
decylamine-N-oxide (C11DAO) in buffer A. Step gradients of imidazole
(0, 16, 30 and 160 mM in buffer A) were used to elute DHODH.
DHODH began to elute with 30 mM imidazole, as indicated by the
appearance of a yellow color in the eluate. At this point, pure DHODH
was rapidly eluted with 160 mM imidazole. The yield of pure DHODH
was typically 40 mg/l of culture. Selenomethionine incorporation into
human DHODH was expressed as described in [24] and purified as
above. The His10 tag was not removed for further studies.
Crystallization and data collection
Human DHODH was co-crystallized with a brequinar analog or
A771726 at 20°C using the hanging-drop diffusion method. Drops
were formed by mixing equal amounts of 20 mg/ml protein in 10 mM
C11DAO, 400 mM NaCl, 30% glycerol, 1 mM EDTA, 50 mM HEPES
pH 7.7, with a precipitant solution of 0.1 M acetate pH 4.8, 40 mM
C11DAO, 20.8 mM N,N-dimethyldecylamine-N-oxide (DDAO), 2 mM
DHO 2.4–2.6 M ammonium sulfate, 1 mM brequinar analog or
A771726, against 1 ml reservoir of 0.1 M acetate pH 4.8, 2.4–2.6 M
ammonium sulfate, 30% glycerol. Crystals usually appeared in three
days and reached the full size of 0.15 × 0.15 × 0.15 mm in two weeks.
It was observed that detergent DDAO, substrate dihydroorotate (or
product orotate) and inhibitor were all necessary for crystallization. The
crystals belonged to space group P3221, with a = b = 90.61 and
c = 122.41 Å. Crystals were flash frozen in liquid nitrogen. During data
collection crystals were kept at 100K in a cool nitrogen stream. Single
wavelength crystal data were collected at CHESS A1. MAD data were
collected at CHESS F2 on a SeMet crystal complexed with brequinar.
The reflection intensities were integrated and processed using the
CCP4 program suite [25] (Table 1). The 2′-desfluoro brequinar analog
used in this study has essentially the same potency against human
DHODH and the human mixed lymphocyte reaction as brequinar (data
not shown).
Structure determination and refinement
A phasing model of the brequinar complex was found using the MAD
phasing method. Direct methods (SHELXL-97) [26] found four of the
five selenium positions from the MAD |λ1–λ3| dispersive signal. All
selenium atoms were confirmed by self- and cross-vector peaks on the
anomalous and dispersive Patterson maps, which were virtually noise
free. Selenium position refinement and phase calculations were carried
out with MLPHARE [27]. The electron-density map was improved by a
solvent-flattening and histogram-matching method using the DM
program [28]. The experimental map was so excellent that brequinar,
FMN and ORO are clearly interpretable and the mainchain and
sidechain atoms of all protein residues except two flexible loops,
Arg70–Arg72 and Arg222–Gln225, can be identified. The initial bre-
quinar complex model was built into the electron-density map using the
program O [29] and refined against all available reflection data using
the programs CNS [30] and REFMAC [31]. In the final brequinar
complex model there are 2760 protein atoms, one molecule of bre-
quinar analog, FMN, detergent DDAO and ORO, a sulfate and an
acetate ion, and 288 water molecules. The model is well refined and
has good geometry (Table 1). The A771726 complex structure was
solved using the difference Fourier method. A771726 was located in
the electron-density map phased with the brequinar complex model,
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Table 1
Data collection and refinement statistics.
Crystal SeMet Brequinar A771726
X-ray source CHESS F2 CHESS A1 CHESS A1
Wavelength (Å) 0.9792/0.9790/0.9633 0.936 0.9134
Resolution (Å) 2.0 1.6 1.8
Observations 305,531/305,836/305,526 444,987 264,642
Unique reflections 39,802/39,841/39,806 75,457 54,515
Completeness 99.4 (100)/99.4 (100.0)/99.3 (100) 97.1 (84.8) 99.0 (99.8)
Redundancy 7.7/7.7/7.7 5.9 4.9
Rsym 8.5 (28.9)/8.9 (32.0)/8.3 (28.2) 4.0 (21.0) 7.9 (20.4)
Phasing (SeMet MAD)
Rdispersive (%) λ1–λ3: 5.1/λ2–λ3: 4.5
Ranom (%) 4.2/4.2/3.5
FOM* (before DM) 0.489 ( 0.174)
FOM* (after DM) 0.736 (0.544)
Refinement
R factor (%) 16.9 (16.6) 16.2 (17.6)
Rfree (%) 18.8 (19.4) 18.5 (20.7)
Bond length (Å) 0.009 0.01
Bond angle (°) 2.0 2.2
Values in parentheses are for the highest resolution data: 2.0–2.1 Å for SeMet, 1.8–1.9 Å for A771726, and 2.0–2.1 Å for brequinar. *FOM, figure
of merit. 
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with brequinar and water molecules removed. The final model was well
refined against all available data with good geometry (Table 1). There
are 2778 protein atoms, one molecule of A771726, FMN and ORO, a
sulfate and acetate ion, and 297 water molecules in the final A771726
complex model. In both the brequinar and A771726 complex struc-
tures, loop Arg70–Arg72 is disordered. Loop Asn212–Gly226 has
higher temperature factors and has different conformations in different
crystals. Within this loop, Arg222–Gln225 is missing in the brequinar
complex but is visible in the A771726 complex structures. The His10
tag and the linker peptide are not visible in all models. 
Accession numbers
The coordinates of both complexes have been deposited in the Protein
Data Bank with accession codes 1D3G and 1D3H.
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